Remifentanil was a μ-agonist, with a rapid onset, a powerful narcotic analgesic activity and a fast nonspecific esterases hydrolyzation and theoretically an ideal opioid for percutaneous dilatational tracheostomy (PDT). The present study discussed use of remifentanil in critically ill patients undergoing PDT. Ninety-nine patients were randomly assigned to the propofol/remifentanil group (PR group, n = 49) or the propofol group (P group, n = 50). Two patients (one in P group and one in PR group) were excluded and transferred to surgical way of tracheostomy because of uncontrolled bleeding. The primary outcomes were critical care pain observation (CPOT) scores during PDT; hemodynamic response and side effects, such as bleeding and muscle rigidity (MR). CPOT scores in P group were significantly higher than in PR group during incision and dilation stages (P < 0.05 and P < 0.01). Systolic blood pressure had a significant drop after a bolus of remifentanil in PR group compared with patients in P group (P < 0.056). The incidence of MR was significantly higher in PR group than in P group (P < 0.05). Recovery time in PR group was significantly shorter than in P group (P < 0.05). The occurrence of tachycardia, bleeding, vomiting, and nausea had no statistically differences in both groups. Patients in PR group were undergoing shorter recovery time and better experience of pain in PDT compared with patients in P group, but MR seemed to be higher in PR group. Remifentanil seemed to be a safe and effective opioid used in critically ill patients undergoing PDT.
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| INTRODUCTION
Percutaneous dilatational tracheostomy (PDT) is one of the most widely utilized procedures in intensive care unit (ICU). 1, 2 Comparing with the surgical way of tracheostomy, PDT shows the equal safety and effectiveness, and suggests a lower rate of tracheal stenosis and a decreased risk of major bleeding and stoma infection. 3 PDT may add potential benefits to the treatment of critically ill patients by increasing patients' comfort, reducing the need for sedation, facilitating the sputum suction and shortening the ICU stay. 4 Despite this, no guidelines have been developed to direct this procedure.
The analgesia and sedation ways are also verified in different regions and countries, procedural pain caused by PDT has been not known either. As we all know, procedural pain is very common in adult ICU patients, 5 by exaggerating neuroendocrine stress response, provoking increased secretion of pituitary hormones, cortisol and catecholamines, making the vital signs unsteady. 6 Chose the ideal pattern of anesthesia is the best way to deal with procedural pain during PDT.
An international survey of tracheostomy procedure in ICU shows sedation-analgesia and local anesthesia are both the most frequently used in PDT. 4 But in local anesthesia, the notable fluctuation of heart rate (HR), blood pressure (BP) and the movement of the body or arms might suggest uncomfortableness, which might indicate insufficient anesthesia. Intravenous opioids are recommended to treat procedural pain in critically ill patients. 5 Remifentanil is a μ-agonist, characterized by an ultra-fast onset, an ultra-short half-time, an organ-independent metabolism, with a hemodynamic bluntness trait, and theoretically an ideal opioid for PDT procedure. However, there have been no randomized-controlled trials on the effect of remifentanil during PDT.
The aim of our study is to evaluate the effects and side effects of remifentanil during PDT. 
| MATERIALS AND METHODS

| Patients information
| Study design
Using random number table, patients were assigned to the propofol group (P group) or propofol/remifentanil group (PR group). Preprocedural sedation was forbidden with the potential influences to the outcome of the study. Starting with the procedure, patients in P group hydrochloride injection, 100 mg/5 mL). Then an ICU physician skilled at PDT started the procedure guided by fiberobronchoscopy. The study data were recorded by an observer who was also blinded to the patient's group assignment.
| Anesthetic monitoring
Patients were under the standard anesthetic monitoring, including electrocardiography, systolic blood pressure (SBP), and peripheral oxygen saturation (SpO 2 ). After a 10 minutes interval, baseline data for HR, mean arterial pressure (MAP), and critical care pain observation (CPOT) scores (Supporting Information Table S1 ) were recorded (T1). The level of pain was evaluated using CPOT. CPOT scores were measured on a scale of 0-8, where 0-2 represented endurable pain, >2 represented pain intolerably. 
| Evaluation of hemodynamic and COPT variables
| Visual analogue scale scores
Consciousness identified as the patients could complete the simple mandatory actions like eye movement, mouth opening, and head nodding. The visual analogue scale (VAS) was got from the patients when they got consciousness (T6), and at 10 minutes (T7), 20 minutes (T8), 30 minutes (T9) after T6.
| Statistics analysis
All statistics analysis were performed by SPSS 16.0 (SPSS, Chicago, Illinois). Results were expressed as mean ± SD. Comparison of means between groups was tested by two-tailed t test for equality of means for independent samples. Chi-squared was used to compare the proportion of patients between groups. P < 0.05 was considered statistically significant.
3 | RESULTS
| Patients
Ninety-nine patients were included in the study, including P group (n = 50) and PR group (n = 49) ( Table 1 ). The age, gender, body mass index, and procedure time between P group and PR group showed no statistically significant differences (P < 0.05). The number of hypertension and diabetes mellitus patients had no differences in two groups (P < 0.05). Two patients were excluded and transferred to surgical way of tracheotomy in emergency because of uncontrollable bleeding.
| Hemodynamic and COPT scores in two groups
No statistically significant differences were found in SBP, HR, and CPOT between the two groups in baseline values. Compared with P group, there was an obvious drop in SBP values in PR group after a bolus injection of remifentanil and topical anesthesia (P < 0.05).
And the differences lasted to incision stage (P < 0.01). CPOT was notably different in both groups during the stages of incision and dilation (P = <0.05 and < 0.01, respectively). Patients in P group showed a higher CPOT than in PR group, which might mean the pain they suffered was greater. HR was similar for P group at all times as compared to PR group from T1 to T5 (P > 0.05) ( Table 2 ).
| Recovery time and total doses
There were significant differences between the two groups on the time to recover and total doses of propofol. The recovery time from the stop of general anesthesia was significantly shorter in PR group (7.68 ± 3.12) minutes than in P group (10.26 ± 2.47) minutes (P < 0.05). The total doses of propofol administrated to the patients were (120 ± 27) mg in P group vs (90 ± 15) mg in PR roup (P < 0.05).
| Adverse effects
The occurrence of hypertension in P group was higher than PR group (P < 0.01). To the contrary, the occurrence of hypotension in P group was lower than PR group (P < 0.05). MR appeared in 4.1% of the patients in PR group compared with 0 in P group (P < 0.05). The occurrence of tachycardia, bleeding, vomiting, and nausea had no statistically differences in both groups (P > 0.05) ( Table 3 ).
| VAS scores
VAS measured by the patients from the time of recovery from consciousness (T6) to 10 minutes (T7), 20 minutes (T8), 30 minutes (T9) interval respectively in each groups (Table 4) . Patients in PR group showed a notably lower experience of pain after PDT than patients in P group. There were significantly statistical differences between the two groups at each time point.
| DISCUSSION
Critically ill patients with respiratory failure caused by Guillain-Barre syndrome, myasthenia gravis, chronic obstructive pulmonary disease, severe pneumonia, thorax trauma, etc. usually need a prolonged time of MV. PDT may add potential benefits to the treatment of critically ill patients who needs MV. 4 Nowadays, PDT has become a regular procedure in ICU. 7, 8 But the procedure pain caused by PDT is under estimated. Control procedure pain is highlighted in the guidelines published on the management of pain in ICU. 5, 9 Comparing with the fast improvement of PDT technique, there is only a few literatures talking about the anesthesiology during the procedure. Dong et al.
suggest patients undergoing PDT in general anesthesia has more comfortability, more stable hemodynamics than topical anesthesia. 10 An international survey of tracheostomy procedure in ICU shows fentanyl and remifentanil are the most used drugs for general anesthesia, but local anesthesia is also popular. Choice of analgesia depends on the type of physician performing PDT. 4 In our study, both of the two groups are given general anesthesia.
The heart inhibition of remifentanil is an important risk factor in our study, especially at the bolus time. But HR between the two groups has no statistical differences during the procedure. Which is in line channel in arterial smooth muscle may be the reasons. [14] [15] [16] [17] Another primary side effect of remifentanil is the inhibition of respiration. We do not take respiration rate and SpO 2 as observation variables because our patients are under volume control ventilation. MV hugely influences the variables, making the biases uncontrollable. That is the difference from other researches. [18] [19] [20] The total doses of propofol in PR group are significantly fewer than that used in P group. Patients in P group need more propofol to help control BP and ease the pain. The increased SBP and CPOT may indicate insufficient anesthesia. The recovery time is a little longer in P group than in PR group accordingly due to a larger use of propofol. In Haytural et al.'s research in which the patients undergo endoscopic retrograde cholangiopancreatography (ERCP), patients in the propofol group need more propofol than the other groups using remifentanil and fentanyl along with propofol, which is the same like our study. 
T A B L E 1 Patients characteristics
| CONCLUSIONS
This study shows that the combination of remifentanil and propofol provide a good condition, a shorter recovery time and a better control of pain in PDT. Remifentanil seems to be a safe and effective opioid in critically ill patients. Further studies should focus on the use of remifentanil in this population in other procedures.
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